PT-141 5mg

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist that was derived from melanotan II research. It is the first and only FDA-approved melanocortin-based therapeutic, approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. PT-141 differs from MT-II by a single modification — the C-terminal amide is replaced with a free carboxylic acid — which alters its receptor selectivity and pharmacokinetic profile. PT-141's mechanism of action for sexual function is mediated primarily through MC4R activation in the central nervous system, particularly in hypothalamic regions involved in sexual arousal and desire. Unlike phosphodiesterase-5 inhibitors (sildenafil, etc.) which act peripherally on vascular smooth muscle, PT-141 acts centrally to modulate sexual desire and arousal pathways. This represents a fundamentally different pharmacological approach — it targets the 'wanting' component of sexual response rather than the mechanical erectile response. The peptide crosses the blood-brain barrier and activates MC4R-expressing neurons in the medial preoptic area and paraventricular nucleus of the hypothalamus. Downstream signaling involves oxytocin release and modulation of dopaminergic pathways. Phase III clinical trials demonstrated statistically significant improvements in sexual desire and reductions in distress associated with low sexual desire.

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist that was derived from melanotan II research. It is the first and only FDA-approved melanocortin-based therapeutic, approved in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. PT-141 differs from MT-II by a single modification — the C-terminal amide is replaced with a free carboxylic acid — which alters its receptor selectivity and pharmacokinetic profile. PT-141's mechanism of action for sexual function is mediated primarily through MC4R activation in the central nervous system, particularly in hypothalamic regions involved in sexual arousal and desire. Unlike phosphodiesterase-5 inhibitors (sildenafil, etc.) which act peripherally on vascular smooth muscle, PT-141 acts centrally to modulate sexual desire and arousal pathways. This represents a fundamentally different pharmacological approach — it targets the 'wanting' component of sexual response rather than the mechanical erectile response. The peptide crosses the blood-brain barrier and activates MC4R-expressing neurons in the medial preoptic area and paraventricular nucleus of the hypothalamus. Downstream signaling involves oxytocin release and modulation of dopaminergic pathways. Phase III clinical trials demonstrated statistically significant improvements in sexual desire and reductions in distress associated with low sexual desire.

The FDA-approved dose of bremelanotide is 1.75 mg subcutaneously. Clinical trials studied doses from 0.75 mg to 4 mg. Earlier intranasal studies used higher doses (10-20 mg) due to lower bioavailability via that route.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.